News Innovent files high-dose mazdutide for obesity in China Innovent has filed a new high-strength version of its weight-loss drug mazdutide in China, aiming to help people with severe obesity.
News Pressure rises on Novo as Innovent drug tops Ozempic Innovent's dual glucagon and GLP-1 agonist mazdutide outperforms Novo Nordisk's Ozempic in overweight people with diabetes.
News Innovent throws its hat further into China's GLP-1 ring Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and E
News Novartis CEO joins board of "responsible" AI firm Anthropic In another signal of the deepening relationship between the pharma and AI sectors, Novartis CEO Vas Narasimhan has joined the board of Anthropic.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.